S3I-201

For research use only. Not for use in humans.

目录号:S1155 别名: NSC 74859

S3I-201 Chemical Structure

CAS No. 501919-59-1

S3I-201 (NSC 74859) 有效抑制STAT3的DNA结合活性,IC50为86 μM,而对STAT1和STAT5的抑制活性低。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 638.93 现货
RMB 563.02 现货
RMB 972.36 现货
RMB 3028.28 现货
RMB 8165.43 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的S3I-201发表文献177篇:

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述 S3I-201 (NSC 74859) 有效抑制STAT3的DNA结合活性,IC50为86 μM,而对STAT1和STAT5的抑制活性低。
特性 S3I-201是化学探测器抑制剂,可以除去乳腺瘤。
靶点
STAT3 [1]
(Cell-free assay)
86 μM
体外研究

S3I-201选择性抑制Stat3 DNA结合活性。S3I-201抑制Stat3·Stat3复合形式,不依赖于Stat3的激活状态。S3I-201不干涉Lck SH2与同源pTyr肽结合。S3I-201作用于NIH 3T3/v-Src鼠成纤维细胞和人类乳腺癌MDA-MB-231, MDA-MB-435, 和MDA-MB-468 细胞,可以抑制Stat3激活。S3I-201 抑制Stat3依赖的转录活性。 S3I-201 也抑制编码cyclin D1, Bcl-xL,和surviving 的Stat3-调节基因的表达。[1]S3I-201可以降低 pS727STAT3水平和降低TGF-β通路蛋白水平。S3I-201也可抑制CD133+ 和CD133− Huh-7细胞。[2]最新研究显示S3I-201作用于Hep-G2, Huh-7和SK-HEP-1细胞,加强 Cetuximab的抗增殖效果。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U87 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DaN|czKGh? MWHJR|UxRTV3LkGg{txO NVj6SnlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwO|I3PTJpPkKwNFczPjV{PD;hQi=>
U373  NXnoW2JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWxO|IhcA>? MVLJR|UxRTV{LkWg{txO MlW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByN{K2OVIoRjJyMEeyOlUzRC:jPh?=
HPAC M3\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C1Z|czKGh? NUHKVFJXUUN3MP-8olExOCEQvF2= NFK5XVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC3NlY2Oid-MkCwO|I3PTJ:L3G+
PANC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\VS|F5PzJiaB?= NWPpSI5nUUN3MP-8olExOCEQvF2= NI\iSZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC3NlY2Oid-MkCwO|I3PTJ:L3G+
SK-BR-3 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPiO|IhcA>? MWXJR|Ux97zgMUCwJO69VQ>? MmC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByN{K2OVIoRjJyMEeyOlUzRC:jPh?=
 U-373 MG NV;Ic4I2S3m2b4TvfIlkcXS7IFHzd4F6 M1jTb|MwOTBizszN Mmf6NlQhcA>? M1vxOJJm\HWlZYOgSm4u|rNvaX7keYNm\CClZXzsJI5mfXKxdH;4bYNqfHl? M2jVRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi4OFE3Lz5{MEi4PFQyPjxxYU6=
MDA-MB-231 M2HyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfuO|IhcA>? MXzJR|Ux97zgMUCwJO69VQ>? NYTOXZBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwO|I3PTJpPkKwNFczPjV{PD;hQi=>
HUVEC  NUnUS2dPTnWwY4Tpc44hSXO|YYm= M4K4PVAvPS1{MDFOwG0> M{HBbVI1KGh? MmXYSG1UVw>? M4\OcpN2eHC{ZYPz[ZMhfGinIHj5dI95cWFvaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> MkfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MkO1OVkoRjJzNUKzOVU6RC:jPh?=
Huh7 NGjEe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ZU2tPOTByIH7N M1G5bFQ5KGh? MXfEUXNQ MkO4bY5pcWKrdIOgeIhmKEmOLU[gd5RqdXWuYYTpc44heHKxbX;0[YQh[2WubDDwdo9tcW[ncnH0bY9v NFHzRZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2OFM5QSd-MkOzOlQ{QDl:L3G+
PLC/PRF/5  Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUexNFAhdk1? MmTTOFghcA>? NEnlUJJFVVOR NI\qO2NqdmirYnn0d{B1cGViSVytOkB{fGmvdXzheIlwdiCycn;tc5Rm\CClZXzsJJBzd2yrZnXyZZRqd25? NF3SdFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2OFM5QSd-MkOzOlQ{QDl:L3G+
H460  MoHkSpVv[3Srb36gRZN{[Xl? M{nJT|UxNzFyMDFOwG0> NH2wN5c1QCCq NFPETY1qdmirYnn0d{B1cGViU4TheFNEKGmwY4LlZZNm\CCvaWKtPVJiKGW6cILld5Nqd25? NIrMNIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyNFI2PCd-MkO4NlAzPTR:L3G+
H1299 MofUSpVv[3Srb36gRZN{[Xl? M4\MZlUxNzFyMDFOwG0> M1P2W|Q5KGh? Mmn3d5VxeHKnc4Pld{BucVJvOULhJIV5eHKnc4Ppc44h\G:|ZT3k[ZBmdmSnboTsfS=> NYPLV3VWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NlAzPTRpPkKzPFIxOjV2PD;hQi=>
T-cell  NEfIUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVyIN88US=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4OEezNUc,OjRyNki3N|E9N2F-
U373  M1zYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETQOGIyOjVizszN NHfqclYzPCCq NVvEToc6TE2VTx?= NEH5flFlcXO{dYD0d{BUXEGWMzDzbYdv[WyrbnegZY5lKHC{b3zp[oVz[XSrb36= M17ofFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEewPFIxLz5{NEC3NFgzODxxYU6=
HUT-102 M4K5fmFxd3C2b4Ppd{BCe3OjeR?= MXq3OU0{ODBizszN NHT2cYUzPC92ODDo MmG4d5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[W6mIHnu[JVk\XNiY3XscEBieG:ydH;zbZPDqA>? NH\oN5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5NFk6PSd-MkSwPVA6QTV:L3G+
MT-2 MXnBdI9xfG:|aYOgRZN{[Xl? NHzpN3c4PS1|MECg{txO NEXBdY8zPC92ODDo NU[wfWo5e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJiYX7kJIlv\HWlZYOgZ4VtdCCjcH;weI9{cXQEoB?= NYDScpN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVA6QTVpPkK0NFkxQTl3PD;hQi=>
H460  M1f5WGFxd3C2b4Ppd{BCe3OjeR?= MVuxNFDDqG6P NH;tZlAzPMLiaB?= MmjR[Y5p[W6lZYOgZ4VtdCCmZXH0bEBkdy22cnXheIVlKHerdHigUHkzQTRyMEK= NHHnSoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NlU{QCd-MkS0O|I2Ozh:L3G+
A459 Ml3pRZBweHSxc3nzJGF{e2G7 NF;wfVkyODEEoH7N MYWyOOKhcA>? MWPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxLYTy[YF1\WRid3n0bEBDTVp{M{W= M1S0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEeyOVM5Lz5{NES3NlU{QDxxYU6=
H460  NWruVld{SXCxcITvd4l{KEG|c3H5 M2\uSlExOMLibl2= MlrTNlTDqGh? M1TUfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3:teJJm[XSnZDD3bZRpKEKHWkKzOS=> NWLPdoVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|I2OzhpPkK0OFczPTN6PD;hQi=>
GC  NWrvXIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DyO|UxNTF{NTFOwG0> NXvLelFGPzJiaB?= MYfheJRmdnWjdHXzJJRp\SClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFm0SZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3OFUxOyd-MkW3O|Q2ODN:L3G+
GH3 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXCbmVPPTBvMUK1JO69VQ>? MWe3NkBp MWPheJRmdnWjdHXzJJRp\SClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5NEWwN{c,OjV5N{S1NFM9N2F-
BT474R  M2PCfGZ2dmO2aX;uJGF{e2G7 NWWx[5NnPTBizszN NH3a[5gyOC14MDDk M2fmR4lvcGmkaYTzJHNVSVR|IHHjeIl3cXS7 M1vMUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{K3OVYyLz5{NUOyO|U3OTxxYU6=
NCI-N87R NITkc5dHfW6ldHnvckBCe3OjeR?= NXTqXnZxPTBizszN MXOxNE03OCCm NGW5[XhqdmirYnn0d{BUXEGWMzDhZ5Rqfmm2eR?= NXPxTG96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNlc2PjFpPkK1N|I4PTZzPD;hQi=>
MDA-MB-468 NHTwZo9HfW6ldHnvckBie3OjeR?= NGS3R2EyODBidV2= NHHzOIYzPCCqcoO= NITrSG5KdmirYnn0bY9vKG:oIGP0ZZQ{KGGldHn2ZZRqd25iaX6gbJVu[W5iTVTBMW1DNTR4ODDj[YxteyCjdDCxNFAhfU1iYX\0[ZIhOjRiaILz NEfMUGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S2N|A6OCd-MUe0OlMxQTB:L3G+
MDA-MB-435 M2LL[mZ2dmO2aX;uJIF{e2G7 NYe5NFhOOTByIIXN MWiyOEBpenN? MUjJcohq[mm2aX;uJI9nKFO2YYSzJIFkfGm4YYTpc44hcW5iaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{BifCBzMECgeW0h[W[2ZYKgNlQhcHK| MoPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2NkOwPVAoRjF5NE[zNFkxRC:jPh?=
MDA-MB-231 NUe1S5Y2TnWwY4Tpc44h[XO|YYm= NFT1ZlEyODBidV2= M2TXXFI1KGi{cx?= MWnJcohq[mm2aX;uJI9nKFO2YYSzJIFkfGm4YYTpc44hcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BifCBzMECgeW0h[W[2ZYKgNlQhcHK| MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR4M{C5NEc,OTd2NkOwPVA9N2F-
NIH3T3 M3vIRmZ2dmO2aX;uJIF{e2G7 MUGxNFAhfU1? MXyyOEBpenN? NWXHdIZFWmWmdXP0bY9vKG:oIIDUfZIuPzB3IGP0ZZQ{KGyndnXsJIlvKHZvU4LjJIV5eHKnc4PpcochdW:3c3WgUmlJO1R|IHPlcIx{KGG2IEGwNEB2VSCjZoTldkAzPCCqcoO= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR4M{C5NEc,OTd2NkOwPVA9N2F-
NIH3T3 M3;uSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWGxNFAhfU1? NEL1eGQ1KGSjeYO= NHfZOo5Iem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBPUUh|VEOgZ4VtdHNiZYjwdoV{e2mwZzD2MXNz[yCjdDCxNFAhfU1iYX\0[ZIhPCCmYYnzJIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDhd5NigQ>? NYX2c5VYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OlMxQTBpPkG3OFY{ODlyPD;hQi=>
MDA-MB-435 MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXzPe|FMOTByIIXN NUPOOJBxPCCmYYnz M3LC[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOg[ZhxemW|c3nu[{B3NVO{YzDheEAyODBidV2gZYZ1\XJiNDDkZZl{KGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeR?= MoG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2NkOwPVAoRjF5NE[zNFkxRC:jPh?=
MDA-MB-231 NILMXGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjZcHg5OTByIIXN M{XMeFQh\GG7cx?= NXvHdZJpT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BmgHC{ZYPzbY5oKHZvU4LjJIF1KDFyMDD1UUBi\nSncjC0JIRigXNiYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5 MkDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2NkOwPVAoRjF5NE[zNFkxRC:jPh?=
MDA-MB-468 MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVvZT5ZDOTByIIXN NYLKfG9mPCCmYYnz MXnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHX4dJJme3Orbnegek1UemNiYYSgNVAxKHWPIHHmeIVzKDRiZHH5d{BjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[Xl? NEDmPGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S2N|A6OCd-MUe0OlMxQTB:L3G+
NIH3T3 MkO0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFTYeVEyODBidV2= MWfHdo94fGhiaX7obYJqfGmxbjDv[kBud3W|ZTDOTWg{XDNiY3XscJMh\XiycnXzd4lv\yC4LWLhd{BifCBzMECgeW0h\m:{IHX2[ZJ6KDNiZHH5d{BjgSC|b3\0MYFo[XJiY3;sc456NW[xcn3heIlwdiCjc4PhfS=> NXGzdWoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OlMxQTBpPkG3OFY{ODlyPD;hQi=>
MDA-MB-435 NFLabFlCeG:ydH;zbZMh[XO|YYm= NIX1ZYU{OCC2bzCxNFAhfU1? MnvNOFghcHK| MW\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2GQT3NRk01OzViY3XscJMh\XiycnXzd4lv\yCjY4TpeoUhW3SjdEOgZZQhOzBidH:gNVAxKHWPIHHmeIVzKDR6IHjydy=> M{O2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NE[zNFkxLz5zN{S2N|A6ODxxYU6=
MDA-MB-231 M{jFR2Fxd3C2b4Ppd{Bie3OjeR?= MnHxNVAxKHWP NUP3b|NnOjRiaILz NXXURZdQWmWmdXP0bY9vKG:oIHHwc5B1d3OrczDpckBUfGG2MzD0doFve2[nY4Tl[EBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHH0JFExOCC3TTDh[pRmeiB{NDDodpM> NETLeXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S2N|A6OCd-MUe0OlMxQTB:L3G+
MDA-MB-231 NV7leGx6TnWwY4Tpc44h[XO|YYm= MXWxNFAhfU1? NIPZcHU1QCCqcoO= NHzqSZpT\WS3Y4Tpc44hd2ZiY4njcIlvKERzIHflcoUh\XiycnXzd4lwdiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG2IEGwNEB2VSCjZoTldkA1QCCqcoO= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR4M{C5NEc,OTd2NkOwPVA9N2F-
MDA-MB-231 NVvVfldMSXCxcITvd4l{KGG|c3H5 Mnn1NVAxKHWP Mkf3NlQhcHK| MnOwTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDTeIF1OyCVSEKg[I9u[WmwIITyZY5{\mWldHXkJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDJ2IHjydy=> NYHZdmp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OlMxQTBpPkG3OFY{ODlyPD;hQi=>
MDA-MB-231 Mn\lRZBweHSxc3nzJIF{e2G7 NHnRfYUyODBidV2= M2XvcVI1KGi{cx?= NVf4XG04UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBUfGG2M1OgeJJidnOoZXP0[YQhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAyODBidV2gZYZ1\XJiMkSgbJJ{ NX[ydHVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OlMxQTBpPkG3OFY{ODlyPD;hQi=>
NIH3T3 NYnlPYt6TnWwY4Tpc44h[XO|YYm= NY\UZoRVOTByIIXN NYfOPWNEPDhiaILz NEH5WG9T\WS3Y4Tpc44hd2ZiY4njcIlvKERzIHflcoUh\XiycnXzd4lwdiCrbjD2MXNz[yC2cnHud4Zm[3SnZDDtc5V{\SCQSVizWFMh[2WubIOgZZQhOTByIIXNJIFnfGW{IES4JIhzew>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR4M{C5NEc,OTd2NkOwPVA9N2F-
NIH3T3 M4jiTGZ2dmO2aX;uJIF{e2G7 NV3WbVVyOTByIIXN MYG0PEBpenN? NVnSZlRiWmWmdXP0bY9vKG:oIFLjcE15VCCpZX7lJIV5eHKnc4Ppc44hcW5idj3TdoMhfHKjboPm[YN1\WRibX;1d4UhVkmKM2SzJINmdGy|IHH0JFExOCC3TTDh[pRmeiB2ODDodpM> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR4M{C5NEc,OTd2NkOwPVA9N2F-
NIH3T3 MVjGeY5kfGmxbjDhd5NigQ>? NHHXd2MyODBidV2= Mn7TOFghcHK| NV2xR2dKWmWmdXP0bY9vKG:oIIP1dpZqfmmwIHflcoUh\XiycnXzd4lwdiCrbjD2MXNz[yC2cnHud4Zm[3SnZDDtc5V{\SCQSVizWFMh[2WubIOgZZQhOTByIIXNJIFnfGW{IES4JIhzew>? NYX6S|NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OlMxQTBpPkG3OFY{ODlyPD;hQi=>
MDA-MB-231 MkThSpVv[3Srb36gZZN{[Xl? NYfNZmtCOTByIIXN NF\L[JA1QCCqcoO= NUPSfWJ2WmWmdXP0bY9vKG:oIFLjcE15VCCpZX7lJIV5eHKnc4Ppc44hcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK| M2rlW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NE[zNFkxLz5zN{S2N|A6ODxxYU6=
MDA-MB-231 NYGzXXpSTnWwY4Tpc44h[XO|YYm= MXexNFAhfU1? NGfYV2M1QCCqcoO= MXvS[YR2[3Srb36gc4Yhe3W{dnn2bY4h\2WwZTDlfJBz\XO|aX;uJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZQhOTByIIXNJIFnfGW{IES4JIhzew>? MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2NkOwPVAoRjF5NE[zNFkxRC:jPh?=
MDA-MB-231 MlnyRY51cXS3bX;yJIF{e2G7 NIPqRZM2KG2pL3vn NEXZdmQzKHenZXvz M3PEcGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiZYjwdoV{e2mwZzDhZ5RqfmViU4TheFMhgGWwb3fyZYZ1\WRiaX6gcY92e2ViYYSgOUBu\y:tZzygbZYh\m:{IHX2[ZJ6KDNiZHH5d{Bnd3JiMjD3[YVsew>? NVzBco02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OlMxQTBpPkG3OFY{ODlyPD;hQi=>
NIH3T3 MkXZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTtNVAxKHWP MX3Hdo94fGhiaX7obYJqfGmxbjDv[kBud3W|ZTDOTWg{XDNiY3XscJMh\XiycnXzd4lv\yC4LWPyZ{BifCBzMECgeW0h\m:{IHX2[ZJ6KDNiZHH5d{BjgSC|b3\0MYFo[XJiY3;sc456NW[xcn3heIlwdiCjc4PhfS=> MmTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2NkOwPVAoRjF5NE[zNFkxRC:jPh?=
A673 M{DnUZFJXFNiYYPzZZk> M3vXXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| Mk\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NH7DeoFyUFSVIHHzd4F6 Ml[wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NHHNPFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M{HqNJFJXFNiYYPzZZk> NIPpVpFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NXzDUGlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MYTxTHRUKGG|c3H5 NVLUemZJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / p-STAT3 / Cyclin D1 / Bcl-2 / Nanog / OCT4 / ALDH1 / CD44; 

PubMed: 26556875     


Western blotting shows S3I-201 treatment decrease Cyclin D1, Bcl2 and self-renewal marker Nanog, OCT4, ALDH1, and CD44 in a dose dependent manner. Data shown are representative of three individual experiments.

PD-L1; 

PubMed: 28605599     


The expression level of PD-L1 was measured by Western blotting in a head and neck squamous cell carcinoma cell line (Cal 27 and FaDu), with and without S3I-201. β-Actin was used as the internal protein loading control. PD-L1, programmed death 1 ligand; STAT, signal transducers and activators of transcription; p-STAT3, phosphorylated STAT3.

26556875 28605599
Immunofluorescence
p-STAT3; 

PubMed: 26556875     


Immunoflurosece shows S3I-201 reduce nuclear expression of p-STAT3Tyr705 by confocal microscope. 

Oct4 / Twist ; 

PubMed: 27521216     


Suppression of Oct4 and Twist expression was shown in TW01 CD44/CD24 co-overexpressed cells and CSCs after S3I-201 treatment. Scale bars indicate 20 μm.

26556875 27521216
Growth inhibition assay
Cell viability; 

PubMed: 26813676     


The STAT3 inhibitor (S3I-201) decreases cellular proliferation in HTLV-I/ATL-lines. Cells were treated with 0, 12.5, 25, or 50 μM S3I-201 or dimethyl sulfoxide (DMSO) for 72 hours. The average growth curve is representative of the percentage of proliferation between S3I-201 and DMSO-treated cells. Each cell line was treated at least twice for standard deviation. 1185 (-IL2) cells were washed in phosphate-buffered saline and resuspended in media without IL2, followed by treatment with S3I-201 for 72 hours.

26813676
体内研究 5 mg/kg剂量的S3I-201作用于携带人类乳腺癌(MDA-MB-231)的鼠时,显示出强抑制效果。[1]5 mg/kg剂量的S3I-201作用于Huh-7移植瘤,显示出强抗癌活性,没有明显的外部健康改变或者体重减轻症状。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外Stat3 DNA结合实验和EMSA分析:

100 mL生物素-e-Ac-EPQpYEEIEL-OH (溶于50 mM Tris/150 mM NaCl, pH 为7.5) 加到链霉亲和素包被的96孔微型板的每孔中,在4oC下振荡温育过夜。用PBS/Tween-20冲洗板,然后加入2次200 mL BSA-T-PBS (0.2% BSA/0.1% Tween-20/PBS)。50 mL Lck-SH2-GST 融合蛋白(6.4 ng/ml,溶于BSA-T-PBS中)加到96孔板的每孔中,在室温下振荡处理4小时。转移溶液,用200 mL BSA-T-PBS冲洗4次,然后在每孔中加入100 mL多克隆GST抗体 (100 ng/mL,溶于BSA-T-PBS),4oC下温育过夜。用BSA-T-PBS冲洗后, 在每孔中加入100 mL 200 ng/ml BSA-T-PBS辣根过氧化物酶结合的二抗,然后在室温下温育45分钟。用BSA-T-PBS冲洗4步后,再用PBS-T冲洗3步,然后在每孔中加入100 mL过氧化物酶底物,温育5到15分钟。加入100 mL 1 M硫酸溶液终止过氧化物酶反应,使用ELISA计数板在450nm 处读取吸光值。
细胞实验:[2]
- 合并
  • Cell lines: HCC细胞系包括HepG2, PLC/PRF/5, SNU-449, Huh-7, SNU-398, SNU-182,和SNU-475
  • Concentrations: 25到250 μM
  • Incubation Time: 72小时
  • Method: 5 ×103个细胞接种在含完全培养基的96孔微型板上。培养72小时后,每孔加入100 μL 2 mg/mL MTT溶液测量存活细胞数。2小时后,转移培养基,每孔加入100 μL二甲亚砜溶解甲结晶。使用酶联免疫吸附法计数器在590 nm处读取吸光值。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 6周大的携带MDA-MB-231移植瘤模型的雌性无胸腺裸鼠
  • Dosages: 5 mg/kg
  • Administration: 静脉注射,每周2天或3天。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 73 mg/mL (199.8 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+corn oil
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 365.36
化学式

C16H15NO7S

CAS号 501919-59-1
储存条件 粉状
溶于溶剂
别名 NSC 74859

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

STAT Signaling Pathway Map

相关STAT产品

Tags: 购买S3I-201 | S3I-201供应商 | 采购S3I-201 | S3I-201价格 | S3I-201生产 | 订购S3I-201 | S3I-201代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID